Digi.bio specializes in advancing programmable cell development through the integration of lab-on-a-chip technology and artificial intelligence. Central to their approach is the use of digital microfluidics and electrowetting, which allows for precise manipulation of droplets on a microscale. This technology enables the automation and miniaturization of complex liquid handling protocols, providing researchers with enhanced control over their experimental processes. By leveraging these capabilities, Digi.bio's Desktop Biofoundry and cloud-enabled software facilitate the automation of repetitive laboratory workflows, making it easier for scientists to build genetic circuits and streamline their research.

In addition to their core technologies, Digi.bio offers custom application development for various sectors, including gene editing, cell therapies, diagnostics, and industrial biotechnology. Their platform is designed to support pharmaceutical companies, contract research organizations, and genome engineering firms in creating tailored solutions for workflow automation. By combining their expertise in digital microfluidics with a focus on co-development and licensing opportunities, Digi.bio aims to empower partners to innovate and enhance their product offerings in the life sciences field.

Netherlands

Digi.Bio is bridging the digital and biological world through microfluidic automation and AI. We develop programmable microfluidics platforms, integrated with sensor and AI, to make biology easier to engineer.

Digi.bio

Company Details